Segall Bryant & Hamill LLC purchased a new stake in shares of Chemed Corporation (NYSE:CHE – Free Report) during the first quarter, Holdings Channel reports. The institutional investor purchased 5,695 shares of the company’s stock, valued at approximately $2,293,000.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Cim LLC grew its stake in Chemed by 1.6% in the 1st quarter. Cim LLC now owns 2,325 shares of the company’s stock valued at $878,000 after buying an additional 37 shares in the last quarter. Amundi boosted its holdings in shares of Chemed by 6,982.7% in the first quarter. Amundi now owns 35,555 shares of the company’s stock worth $13,431,000 after acquiring an additional 35,053 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Chemed by 9.4% in the first quarter. EverSource Wealth Advisors LLC now owns 406 shares of the company’s stock worth $153,000 after acquiring an additional 35 shares during the period. California State Teachers Retirement System grew its position in shares of Chemed by 21.4% in the first quarter. California State Teachers Retirement System now owns 16,832 shares of the company’s stock valued at $6,358,000 after purchasing an additional 2,972 shares in the last quarter. Finally, Eversept Partners LP purchased a new position in shares of Chemed in the first quarter valued at $11,731,000. 95.85% of the stock is owned by institutional investors.
Chemed Price Performance
Shares of Chemed stock opened at $539.13 on Wednesday. The company has a current ratio of 0.91, a quick ratio of 0.89 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $7.05 billion, a PE ratio of 27.08, a price-to-earnings-growth ratio of 2.05 and a beta of 0.51. The business’s 50-day moving average price is $471.15 and its 200-day moving average price is $437.76. Chemed Corporation has a 12 month low of $365.20 and a 12 month high of $551.68.
Chemed Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Thursday, May 28th. This represents a $2.40 annualized dividend and a dividend yield of 0.4%. Chemed’s dividend payout ratio (DPR) is 12.05%.
Insiders Place Their Bets
In other news, Director Patrick P. Grace sold 190 shares of the company’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $532.00, for a total value of $101,080.00. Following the completion of the sale, the director owned 3,533 shares of the company’s stock, valued at approximately $1,879,556. This represents a 5.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the transaction, the chief executive officer directly owned 70,418 shares in the company, valued at approximately $37,991,215.18. This represents a 2.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 3,537 shares of company stock valued at $1,782,654. 3.33% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes
A number of research firms recently issued reports on CHE. Wall Street Zen upgraded Chemed from a “hold” rating to a “strong-buy” rating in a research note on Saturday. Royal Bank Of Canada raised their target price on Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 30th. Bank of America reaffirmed a “neutral” rating on shares of Chemed in a report on Wednesday, July 29th. Zacks Research upgraded Chemed from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Oppenheimer increased their price target on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a report on Friday. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $530.75.
Check Out Our Latest Stock Report on CHE
Chemed Company Profile
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
Featured Articles
- Five stocks we like better than Chemed
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE – Free Report).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
